期刊
LABORATORY INVESTIGATION
卷 91, 期 6, 页码 872-884出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/labinvest.2011.41
关键词
fibrosis; HMG-CoA reductase; inflammation; oxidative stress; pancreas
资金
- Sasagawa Japan China Medical Association
- Japan Society for the Promotion of Science [17659222]
- Grants-in-Aid for Scientific Research [17659222] Funding Source: KAKEN
As appropriate therapies for pancreatic fibrosis and inflammation are limited, prognosis of chronic pancreatitis has not improved to date. Recent studies have shown that statins improve inflammation and fibrosis in several organs. We therefore examined the therapeutic effect of pravastatin on progression of chronic pancreatitis by starting this treatment after induction of pancreatic fibrosis in rats. Chronic pancreatitis was induced by continuous pancreatic ductal hypertension (PDH) for 14 days according to our previous study. Pravastatin at a dose of 10 mg/kg/day was administrated directly into the duodenum via cannula from 2 days after induction of PDH. Progression of pancreatic fibrosis and expression levels of transforming growth factor-beta 1 and tumor necrosis factor-alpha mRNA were markedly attenuated after commencement of pravastatin compared with untreated group with PDH. In addition, pravastatin treatment markedly improved pancreatic exocrine function and significantly elevated expression level of interleukin (IL)-10 and superoxide dismutase activity in the pancreas compared with the untreated group with PDH. These results revealed that pravastatin substantially attenuates the progression of pancreatic inflammation, fibrosis and exocrine dysfunction probably by its anti-oxidative property and overproduction of IL-10 in animal model of chronic pancreatitis. These results provide an experimental evidence that pravastatin exerts beneficial effect for progression of chronic pancreatitis. Laboratory Investigation (2011) 91, 872-884; doi:10.1038/labinvest.2011.41; published online 7 March 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据